Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization

Atherosclerosis

Volumn 218, Issue 2, 2011, Pages 272-280

  Descamps, O S ^a   Tenoutasse, S ^b   Stephenne, X ^c   Gies, I ^d   Beauloye, V ^c   Lebrethon, M C ^e   De Beaufort, C ^f   De Waele, K ^g   Scheen, A ^h   Rietzschel, E ^g   Mangano, A ⁱ   Panier, J P ⁱ   Ducobu, J ^j   Langlois, M ^k   Balligand, J L ^c   Legat, P ^l   Blaton, V ^j   Muls, E ^m   Van Gaal, L ⁿ   Sokal, E ^c   Rooman, R ⁿ   Carpentier, Y ^o   De Backer, G ^g   Heller, F R ^a   more..

^a Hospital de Jolimont   (Belgium)

^b HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f Clinique Pédiatrique CH de Luxembourg   (Belgium)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h UNIVERSITY OF LIÈGE   (Belgium)

ⁱ Belgian Patient Association for Familial Hypercholesterolemia   (Belgium)

^j UNIVERSITY OF MONS   (Belgium)

^k Université de Mons ^*  (Belgium)

^l Société Scientifique de Médecine Générale   (Belgium)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^o UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

more..

Author keywords

Apolipoprotein b; Cardiovascular disease; Children; Cholesterol; Diagnostic criteria; Ezetimibe; Familial hypercholesterolemia; Fibrates; LDL receptor gene; Plant sterols; Stanols; Statins; Treatment consensus paper

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CHILD; CHOLESTEROL BLOOD LEVEL; CONTRACEPTION; DIAGNOSTIC PROCEDURE; DIET SUPPLEMENTATION; DIETITIAN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GASTROENTEROLOGIST; GENE MUTATION; GENERAL PRACTITIONER; GENETIC SCREENING; HEALTH CARE ORGANIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPIDOLOGIST; LOW FAT DIET; MEDICAL DECISION MAKING; NUTRITIONIST; PARAMEDICAL PERSONNEL; PEDIATRICIAN; PHYSICAL ACTIVITY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADULT; CARDIOLOGY; CHILD; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DECISION MAKING; FEMALE; GASTROENTEROLOGY; GENERAL PRACTICE; GUIDELINES AS TOPIC; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; NUTRITIONAL SCIENCES; PEDIATRICS; YOUNG ADULT;

EID: 80053292217     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.016     Document Type: Review

References (58)

1. Goldstein J.L., Hobbs H.H., Brown MS Familial hypercholesterolemia. The metabolic and molecular bases of inherited disease 2001, 2863-2913. McGraw-Hill Companies Inc., New York, NY. 8th ed. C.R. Scriver, W.S. Sly, B. Childs, A. et (Eds.).
2. Tsimikas S., Witztum J.L. Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century. J Am Coll Cardiol 2002, 40:2122-2124.
3. Iughetti L., Predieri B., Balli F., Calandra S. Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review. J Endocrinol Invest 2007, 30:700-719.
4. Sorensen K.E., Celermajer D.S., Georgakopoulos D., et al. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 1994, 93:50-55.
5. Lavrencic A., Kosmina B., Keber I., Videcnik V., Keber D. Carotid intima-media thickness in young patients with familial hypercholesterolemia. Heart 1996, 76:321-325.
6. Tonstad S., Joakimsen O., Stensland-Bugge E., et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996, 16:984-991.
7. Raitakari O.T., Juonala M., Kähönen M., et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003, 290:2277-2283.
8. Li S., Chen W., Srinivasan S.R., et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003, 290:2271-2276.
9. Davis P.H., Dawson J.D., Riley W.A., Lauer R.M. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001, 104:2815-2819.
10. Rodenburg J., Vissers M.N., Wiegman A., Trip M.D., Bakker H.D., Kastelein J.J. Familial hypercholesterolemia in children. Curr Opin Lipidol 2004, 15:405-411.
11. Avis H.J., Vissers M.N., Stein E.A., et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007, 27:1803-1810.
12. de Jongh S., Lilien M.R., op't Roodt J., et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002, 40:2117-2121.
13. Wiegman A., Hutten B.A., de Groot E., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004, 292:331-337.
14. Koeijvoets K.C., Rodenburg J., Hutten B.A., et al. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 2005, 112:3168-3173.
15. Civeira F. International panel on management of familial hypercholesterolemia, guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004, 173:55-68.
16. Descamps O.S., Gilbeau J.B., Luwaert R., Heller F. Impact of genetic defects on coronary atherosclerosis in patients suspected of familial hypercholesterolemia. Eur J Clin Invest 2003, 33:1-9.
17. Kwiterovich P.O. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab 2008, 93:4200-4209.
18. McCrindle B.W., Urbina E.M., Dennison B.A., et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007, 115:1948-1967.
19. Wierzbicki A.S., Humphries S.E., Minhas R Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008, 337:a1095. Guideline Development Group, [complete guideline in website (http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf)]. 10.1136/bmj.a1095.
20. van der Graaf A., Kastelein J.J., Wiegman A. Heterozygous familial hypercholesterolaemia in childhood: cardiovascular risk prevention. J Inherit Metab Dis 2009, 32:699-705.
21. The AGREE Collaboration. AGREE Instrument, http://www.agreecollaboration.org/.
22. Zimmet P., Alberti G., Kaufman F., et al. International diabetes federation task force on epidemiology and prevention of diabetes. The metabolic syndrome in children and adolescents. Lancet 2007, 369(9579):2059-2061.
23. Daniels S.R., Greer F.R. Lipid screening and cardiovascular health in childhood. Pediatrics 2008, 122:198-208. Committee on Nutrition.
24. Maahs D.M., Wadwa R.P., Bishop F., et al. Dyslipidemia in youth with diabetes: to treat or not to treat?. J Pediatr 2008, 153:458-465.
25. Descamps O.S., Bruniau M., Guilmot P.F., Tonglet R., Heller F.R. Lipoprotein concentrations in newborns are associated with allelic variations in their mothers. Atherosclerosis 2004, 172:287-298.
26. US Preventive Services Task Force Screening for lipid disorders in children: US preventive task force recommendation statement. Pediatrics 2007, 120:e215-e219.
27. Hakanen M., Lagström H., Kaitosaari T., et al. Development of overweight in an atherosclerosis prevention trial starting in early childhood. The STRIP study. Int J Obes 2006, 30:618-626.
28. Friedman L.A., Morrison J.A., Daniels S.R., McCarthy W.F., Sprecher D.L. Sensitivity and specificity of pediatric lipid determinations for adult lipid status: findings from the Princeton Lipid Research Clinics Prevalence Program Follow-up Study. Pediatrics 2006, 118:165-172.
29. Wiegman A., Rodenburg J., de Jongh S., et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003, 107:1473-1478.
30. Benlian P., Turquet A., Carrat F., et al. Diagnosis scoring for clinical identification of children with heterozygous familial hypercholesterolemia. J Pediatr Gastroenterol Nutr 2009, 48:456-463.
31. Obarzanek E., Kimm S.Y., Barton B.A., et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics 2001, 107:256-264.
32. Poustie V.J., Rutherford P. Dietary treatment for familial hypercholesterolemia. Cochrane Database Syst Rev 2001, 2:CD001918.
33. Sánchez-Bayle M., Soriano-Guillén L. Influence of dietary intervention on growth in children with hypercholesterolemia. Acta Paediatr 2003, 92:1043-1046.
34. Jakulj L., Vissers M.N., Rodenburg J., et al. Plant stanols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. J Pediatr 2006, 148:495-500.
35. Ketomaki A., Gylling H., Miettinen T.A. Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject. J Lab Clin Med 2004, 143:255-262.
36. Amundsen A.L., Ntanios F., Put N., Ose L. Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread. Eur J Clin Nutr 2004, 58:1612-1620.
37. Hooper L., Thompson R.L., Harrison R.A., et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006, 332:752-760.
38. Engler M.M., Engler M.B., Malloy M.J., et al. Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol 2005, 95:869-871.
39. Zhan S., Ho S.C. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutrition 2005, 81:397-408.
40. Weghuber D., Widhalm K. Effect of 3-month treatment of children and adolescents with familial and polygenic hypercholesterolaemia with a soya-substituted diet. Br J Nutr 2008, 99:281-286.
41. Martinez J., Lewi J.E. An unusual case of gynecomastia associated with soy product consumption. Endocr Pract 2008, 14:415-418.
42. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-1278.
43. Donaghue K.C., Chiarelli F., Trotta D., Allgrove J., Dahl-Jorgensen K. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes 2009, 10(Suppl. 12):195-203.
44. Arambepola C., Farmer A.J., Perera R., Neil H.A.W. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis 2006, 195:339-347.
45. Wheeler K.A., West R.J., Lloyd J.K., Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 1985, 60:34-37.
46. Lioudaki E., Ganotakis E.S., Mikhailidis D.P. Ezetimibe, more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol 2011, 9:62-86.
47. Clauss S., Wai K.M., Kavey R.E., Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr 2009, 154:869-872.
48. Groot P.H., Dijkhuis-Stoffelsma R., Grose W.F., Ambagtsheer J.J., Fernandes J. The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia. Acta Paediatr Scand 1983, 72:81-85.
49. Stein E.A., Marais A.D., Szamosi T., et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr 2010, 156:231-236.
50. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 Update. Circulation 2007, 115:1481-1501.
51. Rosendaal F.R., Van Hylckama Vlieg A., Tanis B.C., Helmerhorst F.M. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003, 1:1371-1380.
52. Tuppurainen M., Klimscheffskij R., Venhola M., Dieben T.O. The combined contraceptive vaginal ring (nuvaring) and lipid metabolism: a comparative study. Contraception 2004, 69:389-394.
53. Pollack P.S., Shields K.E., Burnett D.M., et al. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 2005, 73:888-896.
54. Borberg H. 26 years of LDL-apheresis: a review of experience. Transfus Apher Sci 2009, 41:49-59.
55. Sokal E.M., Ulla L., Harvengt C., Otte J.B. Liver transplantation for familial hypercholesterolemia before the onset of cardiovascular complications. Transplantation 1993, 55:432-433.
56. Smets F., Najimi M., Sokal E.M. Cell transplantation in the treatment of liver diseases. Pediatr Transplant 2008, 12:6-13.
57. Akdim F., Stroes E.S., Kastelein J.J. Antisense apolipoprotein B therapy: where do we stand?. Curr Opin Lipidol 2007, 18:397-400.
58. Edwards M., Davis H. Counselling Children with Chronic Medical Conditions 1997, Wiley-Blackwell, [Communication and Counselling in Health Care].